Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment With Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib

NCT04722848 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT04722848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04722848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment With Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 8, 2021
Completion date
September 30, 2027
Enrollment
236 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (philadelphia chromosome positive), all, adult, philadelphia-positive all